Bio-Rad Laboratories, Inc. Clas (NYSE:BIO).
On June 28 the stock rating was upgraded to “Buy” from “” by Deutsche Bank. Equity analyst CL King started coverage with an initial rating of “Buy”.
The company is now up since yesterday’s close of $225.79. Company chares are trading at $226.94 just above $222.92, the 50 day moving average and which is marginally higher than the 200 day moving average of $202.79. The 50 day moving average was up $4.02 or +1.80% and the 200 day average moved up $24.15.
Bio-Rad Laboratories, Inc. (Bio-Rad), launched on March 10, 1975, is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The Business’s Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. The Business’s Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. As of December 31, 2016, Bio-Rad sold more than 8,000 products and services to a client base, including scientific research, healthcare, education and government customers around the world..
The most current P/E ratio is 240.91 and the market value is 6.72B. In the latest earnings report the EPS was $0.94 and is expected to be $2.85 for the current year with 29,605,000 shares outstanding. Next quarter’s EPS is expected be $0.60 with next year’s EPS anticipated to be $4.53.